Open AccessProstate-Specific antigen value and micro RNAs as potential diagnostic biomarkers for prostate cancer
Author(s) -
Aydemir Asdemir,
Sevgi Durna Daştan,
Esat Korğalı,
Tugba Yildiz Asdemir,
Esat Korğalı,
Resul Cicek
Publication year - 2021
Publication title -
medical science and discovery
Language(s) - English
Resource type - Journals
ISSN - 2148-6832
DOI - 10.36472/msd.v8i2.479
Subject(s) - prostate cancer , medicine , microrna , biomarker , prostate , cancer , hyperplasia , pca3 , prostate specific antigen , oncology , gene , biology , biochemistry
Objective: It is necessary to provide PSA alternatives or methods that can be used in conjunction with PSA to regress complications rising from negative biopsies and to increase diagnostic value.
Patients and Methods: The study is consisting of 59 men as the sample group. Blood samples from the individuals are grouped as prostate cancer and BPH (benign prostatic hyperplasia) groups. 27 prostate cancer patients whom some of them also operated are assembled in the patients group and the other 32 individuals are grouped as BPH group. Micro RNA expression levels evaluated by RT-PCR.
Results: Prostate cancer group when compared with the control group, it is observed that expression levels of miRNA-221 and miRNA-432 increased while expression levels of miRNA-17-5p, miRNA-30c, miRNA-107, miRNA-141, miRNA-145, miRNA-181a-2, miRNA-331-3p, miRNA-574-3p decreased and expression levels of miRNA-21 and miRNA-375 are quite similar between the groups.
Conclusion: The prospect of strong and sensitive serum miRNA expression levels in prostate cancer cases which are easily detectable by non-invasive methods as biomarkers is a promising field of study. Nevertheless, it is currently necessary to work in conjunction with both tissue and serum to enhance both sensitivity and specificity of miRNAs as biomarkers. As such, expression levels of the same miRNAs in tissue and serum provide different expression values which in turn make it difficult to indicate a common biomarker.